title: Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment.
authors: Luisa
authors: L
authors: Giaccone
authors: Roberto
authors: R
authors: Sorasio
authors: Francesca
authors: F
authors: Patriarca
authors: Daniele
authors: D
authors: Mattei
authors: Vittorio
authors: V
authors: Montefusco
authors: Jacopo
authors: J
authors: Peccatori
authors: Fabrizio
authors: F
authors: Carnevale-Schianca
authors: Maria Teresa
authors: MT
authors: Petrucci
authors: Giuseppe
authors: G
authors: Milone
authors: Stefano
authors: S
authors: Guidi
authors: Marcello
authors: M
authors: Rotta
authors: Renato
authors: R
authors: Fanin
authors: Paolo
authors: P
authors: Corradini
authors: Mario
authors: M
authors: Boccadoro
authors: Benedetto
authors: B
authors: Bruno
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D016572:Cyclosporine / Q000009:adverse effects*; D004347:Drug Interactions; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D009101:Multiple Myeloma / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011719:Pyrazines / Q000009:adverse effects*; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D007166:Immunosuppressive Agents; D011719:Pyrazines; D000069286:Bortezomib; D016572:Cyclosporine